PSMA Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best development services for PSMA based cancer vaccines. We guarantee the finest results for our customers all over the world.

Prostate Specific Membrane Antigen (PSMA)

Prostate specific membrane antigen (PSMA) is a 100 kDa integral, type II membrane protein with acidic dipeptides activity which is highly expressed in primary and metastatic prostate cancer, and to a lesser extent in normal prostate tissue. PSMA expression increases with disease progression. This well-defined prostate expression is significantly elevated in prostate cancer, especially in advanced stages.

PSMA Based Cancer Vaccines

Besides prostate cancer, PSMA has also been detected in tumor vascular endothelium from a variety of cancers as well as at much lower levels in some normal tissues, including duodenal mucosa and some proximal renal tubules. PSMA immunoreactivity is absent to moderate in most hyperplastic and benign tissues. These features make PSMA an excellent target for prostate cancer immunotherapy. Several PSMA-based vaccines had been developed and clinical trials indicate that these immunotherapy approaches can be safely administered and can induce immune responses in patients with advanced carcinoma of prostate.The relevance of PSMA as a target is emphasized by successful targeting of prostate cancer with ProstaScint, an 111In-labelled anti-PSMA mAb that has been licensed by FDA for this purpose.

To date, the only reports of vaccines containing PSMA involve peptides pulsed onto autologous dendritic cells. In these small studies, indications of immunogenicity were observed, and no obvious toxicity was described. Partial clinical responses were induced is some patients which were durable after one year. These trials indicate that PSMA is an appropriate choice of antigen for this patient population, even in the presence of metastatic disease. These studies are applicable only to HLA A2 positive patients and employed a technique involving ex vivo expansion and manipulation of dendritic cells, making them impractical for wide spread application.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experienced experts and advanced platforms that are able to provide excellent services. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.